Sep 24, 2019
AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

Sep 19, 2019
AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

Sep 16, 2019
AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

Sep 13, 2019
AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

Sep 10, 2019
AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

Sep 09, 2019
AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM'

Sep 06, 2019
AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th

Aug 23, 2019
Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen's® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

Aug 15, 2019
Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

Aug 08, 2019
Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

 6   7   8   9   10     11    12   13   14   15   16